Safety and Efficacy of VB10.16 and Pembrolizumab in Patients with Head-Neck Squamous Cell Carcinoma — StellaPhase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(17 sites)
Czechia
Fakultni nemocnice Olomouc, Olomuoc, Olomouc France
Hôpital de la Pitié - Salpétrière in Paris, Paris, Paris Hospices Civils De Lyon, Lyon CRLC Val d'Aurelle - Institut de Recherche en Cancerologie de Montpellier (IRCM), Montpellier Institut Gustave Roussy, Paris, Paris Germany
Universität Leipzig Klinik und Poliklinik für Hals-, Nasen-, Ohrenheilkunde, Leipzig Hungary
Orszagos Onkologiai Intezet, Budapest, Budapest Norway
University of Bergen, Haukeland University Hospital, Bergen Oslo Universitetssykehus, Oslo Poland
Uniwersyteckie Cetrum Kliniczne, Gdansk Narodowy Instytut Onkologii-im Marii Sklodowskiej-Curie Panstwowy Instytut, Gliwice KO-MED Centra Kliniczne Lublin II, Lublin, Lublin Spain
Hospital del Mar, Barcelona, Barcelona Institut Catala d'Oncologia, Barcelona, Barcelona Hospital Universitario Virgen de las Nieves, Granada, Granada MD Anderson Cancer Center, Madrid, Madrid United Kingdom
East and North Hertfordshire NHS Trust Mount Vernon Hospital, London Last updated December 2024